Research ExplorerPublicationsDoes the Presence of Circulating Tumor Cells in High-Risk Ea...

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial

Standard

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial. / Trapp, Elisabeth K; Fasching, Peter A; Fehm, Tanja; Schneeweiss, Andreas; Mueller, Volkmar; Harbeck, Nadia; Lorenz, Ralf; Schumacher, Claudia; Heinrich, Georg; Schochter, Fabienne; de Gregorio, Amelie; Tzschaschel, Marie; Rack, Brigitte; Janni, Wolfgang; Friedl, Thomas W P.

In: CANCERS, Vol. 14, No. 16, 3949, 16.08.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Trapp, EK, Fasching, PA, Fehm, T, Schneeweiss, A, Mueller, V, Harbeck, N, Lorenz, R, Schumacher, C, Heinrich, G, Schochter, F, de Gregorio, A, Tzschaschel, M, Rack, B, Janni, W & Friedl, TWP 2022, 'Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial', CANCERS, vol. 14, no. 16, 3949. https://doi.org/10.3390/cancers14163949

APA

Trapp, E. K., Fasching, P. A., Fehm, T., Schneeweiss, A., Mueller, V., Harbeck, N., Lorenz, R., Schumacher, C., Heinrich, G., Schochter, F., de Gregorio, A., Tzschaschel, M., Rack, B., Janni, W., & Friedl, T. W. P. (2022). Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial. CANCERS, 14(16), [3949]. https://doi.org/10.3390/cancers14163949

Vancouver

Trapp EK, Fasching PA, Fehm T, Schneeweiss A, Mueller V, Harbeck N et al. Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial. CANCERS. 2022 Aug 16;14(16). 3949. https://doi.org/10.3390/cancers14163949

Bibtex

@article{9fbf12714331492ebc7b165297d9ca92,
title = "Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial",
abstract = "The prognostic relevance of circulating tumor cells (CTCs) in breast cancer is well established. However, little is known about the association of CTCs and site of first metastasis. In the SUCCESS A trial, 373 out of 3754 randomized high-risk breast cancer patients developed metastatic disease. CTC status was assessed by the FDA-approved CellSearch{\textregistered}-System (Menarini Silicon Biosystems, Bologna, Italy) in 206 of these patients before chemotherapy and additionally in 159 patients after chemotherapy. CTCs were detected in 70 (34.0%) of 206 patients before (median 2 CTCs, 1-827) and in 44 (27.7%) of 159 patients after chemotherapy (median 1 CTC, 1-124); 16 (10.1%) of 159 patients were CTC-positive at both timepoints. The site of first distant disease was bone-only, visceral-only, and other-site-only in 44 (21.4%), 60 (29.1%), and 74 (35.9%) patients, respectively, while 28 (13.6%) patients had multiple sites of first metastatic disease. Patients with CTCs at both timepoints more often showed bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) than patients without CTCs before and/or after chemotherapy (p = 0.027). In conclusion, the presence of CTCs before and after chemotherapy is associated with multiple-site or bone-only first-distant disease and may trigger intensified follow-up and perhaps further treatment.",
author = "Trapp, {Elisabeth K} and Fasching, {Peter A} and Tanja Fehm and Andreas Schneeweiss and Volkmar Mueller and Nadia Harbeck and Ralf Lorenz and Claudia Schumacher and Georg Heinrich and Fabienne Schochter and {de Gregorio}, Amelie and Marie Tzschaschel and Brigitte Rack and Wolfgang Janni and Friedl, {Thomas W P}",
year = "2022",
month = aug,
day = "16",
doi = "10.3390/cancers14163949",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "16",

}

RIS

TY - JOUR

T1 - Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial

AU - Trapp, Elisabeth K

AU - Fasching, Peter A

AU - Fehm, Tanja

AU - Schneeweiss, Andreas

AU - Mueller, Volkmar

AU - Harbeck, Nadia

AU - Lorenz, Ralf

AU - Schumacher, Claudia

AU - Heinrich, Georg

AU - Schochter, Fabienne

AU - de Gregorio, Amelie

AU - Tzschaschel, Marie

AU - Rack, Brigitte

AU - Janni, Wolfgang

AU - Friedl, Thomas W P

PY - 2022/8/16

Y1 - 2022/8/16

N2 - The prognostic relevance of circulating tumor cells (CTCs) in breast cancer is well established. However, little is known about the association of CTCs and site of first metastasis. In the SUCCESS A trial, 373 out of 3754 randomized high-risk breast cancer patients developed metastatic disease. CTC status was assessed by the FDA-approved CellSearch®-System (Menarini Silicon Biosystems, Bologna, Italy) in 206 of these patients before chemotherapy and additionally in 159 patients after chemotherapy. CTCs were detected in 70 (34.0%) of 206 patients before (median 2 CTCs, 1-827) and in 44 (27.7%) of 159 patients after chemotherapy (median 1 CTC, 1-124); 16 (10.1%) of 159 patients were CTC-positive at both timepoints. The site of first distant disease was bone-only, visceral-only, and other-site-only in 44 (21.4%), 60 (29.1%), and 74 (35.9%) patients, respectively, while 28 (13.6%) patients had multiple sites of first metastatic disease. Patients with CTCs at both timepoints more often showed bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) than patients without CTCs before and/or after chemotherapy (p = 0.027). In conclusion, the presence of CTCs before and after chemotherapy is associated with multiple-site or bone-only first-distant disease and may trigger intensified follow-up and perhaps further treatment.

AB - The prognostic relevance of circulating tumor cells (CTCs) in breast cancer is well established. However, little is known about the association of CTCs and site of first metastasis. In the SUCCESS A trial, 373 out of 3754 randomized high-risk breast cancer patients developed metastatic disease. CTC status was assessed by the FDA-approved CellSearch®-System (Menarini Silicon Biosystems, Bologna, Italy) in 206 of these patients before chemotherapy and additionally in 159 patients after chemotherapy. CTCs were detected in 70 (34.0%) of 206 patients before (median 2 CTCs, 1-827) and in 44 (27.7%) of 159 patients after chemotherapy (median 1 CTC, 1-124); 16 (10.1%) of 159 patients were CTC-positive at both timepoints. The site of first distant disease was bone-only, visceral-only, and other-site-only in 44 (21.4%), 60 (29.1%), and 74 (35.9%) patients, respectively, while 28 (13.6%) patients had multiple sites of first metastatic disease. Patients with CTCs at both timepoints more often showed bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) than patients without CTCs before and/or after chemotherapy (p = 0.027). In conclusion, the presence of CTCs before and after chemotherapy is associated with multiple-site or bone-only first-distant disease and may trigger intensified follow-up and perhaps further treatment.

U2 - 10.3390/cancers14163949

DO - 10.3390/cancers14163949

M3 - SCORING: Journal article

C2 - 36010945

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 16

M1 - 3949

ER -